Особенности поражения пищевода при постхолецистэктомическом синдроме
https://doi.org/10.31146/1682-8658-ecg-198-2-121-130
Аннотация
Об авторах
Ю. А. ФоминыхРоссия
А. А. Гнутов
Россия
Р. А. Насыров
Россия
Е. Ю. Калинина
Россия
Н. Ю. Колгина
Россия
Список литературы
1. Zimmerman J. S. Postcholecystectomical syndrome, its nature, clinical manifestations, diagnosis and treatment. Experimental and Clinical Gastroenterology. 2017;(8):4-11. (In Russ.)@@ Циммерман Я. С. Постхолецистэктомический синдром, его сущность, клинические проявления, диагностика и лечение. Экспериментальная и клиническая гастроэнтерология 2017;144(8) 4-11.
2. Galiev S.Z., Amirov N. B. Duodenogastric reflux as a cause of reflux-gastritis. Bulletin of Contemporary Clinical Medicine. 2015;8(2):50-61. (In Russ.)@@ Галиев Ш. З., Амиров Н. Б. Дуоденогастральный рефлюкс как причина развития рефлюкс-гастрита. Вестник современной клинической медицины. 2015;8(2):50-61.
3. McQuaid K.R., Laine L., Fennerty M. B., et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34:146-65. doi: 10.1111/j.1365-2036.2011.04709.x
4. Kuran S. Bile reflux index after therapeutic biliary procedures. BMC Gastroenterology. 2008;8:4. doi: 10.1186/1471-230X-8-4
5. Mercan E., Duman U., Tihan D., Dilektasli E., Senol K. Cholecystectomy and duodenogastric reflux: interacting effects over the gastric mucosa. SpringerPlus. 2016;5:1970. doi: 10.1186/s40064-016-3641-z
6. Svensson J., Gelin J., Svanvik J. Gallstones, cholecystectomy, and duodenogastric reflux of bile acid. Scand J Gastroenterol. 1986;21:181-187.
7. Koek G.H., Vos R., Sifrim D., Cuomo R., Janssens J., Tack J. Mechanisms underlying duodeno-gastric reflux in man. Neurogastroenterol Motil. 2005 Apr;17(2):191-9. doi: 10.1111/j.1365-2982.2004.00633.x
8. Richter J. E. Duodenogastric Reflux-induced (Alkaline) Esophagitis. Current Treatment Options in Gastroenterology. 2004; 7: 53-58.
9. Dixon M.F., Neville P. M., Mapstone N. P., Moayyedi P., Axon A. T. Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastro-oesophageal reflux?. Gut. 2001;49(3):359-363. doi:10.1136/gut.49.3.359
10. Brillantino A., Monaco L., Schettino M., Torelli F., Izzo G., Cosenza A., Marano L., Di Martino N. Prevalence of pathological duodenogastric reflux and the relationship between duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1136-43. doi: 10.1097/MEG.0b013e32830aba6d
11. Shah Gilani S. N., et al. Gastroesophageal Mucosal Injury after Cholecystectomy: An Indication for Surveillance? J Am Coll Surg. 2017 Mar;224(3):319-326. doi: 10.1016/j.jamcollsurg.2016.12.003
12. Ivashkin V.T., Mayev I. V., et al. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75-95. (In Russ.) doi: 10.22416/1382-4376-2017-27-4-75-95@@ Ивашкин В. Т., Маев И. В., Трухманов А. С., Баранская Е. К., Дронова О. Б., Зайратьянц О. В., Сайфутдинов Р. Г., Шептулин А. А., Лапина Т. Л., Пирогов С. С., Кучерявый Ю. А., Сторонова О. А., Андреев Д. Н. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(4):75-95.
13. Mayev I.V., Andreyev D. N., Kucheryavy Yu.A., Scheglanova M. P. Esophageal adenocarcinoma: risk factors and modern screening strategy.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):4-12. (In Russ.) doi: 10.22416/1382-4376-2017-27-2-4-12@@ Маев И. В., Андреев Д. Н., Кучерявый Ю. А., Щегланова М. П. Аденокарцинома пищевода: факторы риска и современные стратегии скрининга. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(2):4-12 doi: 10.22416/1382-4376-2017-27-2-4-12
14. Koek G.H., Sifrim D., Lerut T., Janssens J., Tack J. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett’s oesophagus. Gut. 2008 Aug;57(8):1056-64. doi: 10.1136/gut.2006.119206
15. Souza R. F. The role of acid and bile reflux in oesophagitis and Barrett’s metaplasia. Biochem Soc Trans. 2010;38(2):348-352. doi:10.1042/BST0380348
16. Naini B.V., Souza R. F., Odze R. D. Barrett’s Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol. 2016;40(5): e45-e66. doi:10.1097/PAS.0000000000000598
17. Uspenskiy Yu.P., Fominykh Yu.A., Gnutov A. A. Duodenogastroesophageal reflux: current state of issue. Medical alphabet. 2020;(37):11-15. (In Russ.) doi: 10.33667/2078-5631-2020-37-11-16@@ Успенский Ю. П., Фоминых Ю. А., Гнутов А. А. Дуоденогастроэзофагеальный рефлюкс: современное состояние проблемы. Медицинский алфавит. 2020;(37):11-15. doi:10.33667/2078-5631-2020-37-11-16
18. Ilchenko A. A. Bile acids in health and disease. Experimental and clinical gastroenterology. 2010; 4: 3-13. (in Russ.)@@ Ильченко А. А. Желчные кислоты в норме и при патологии. Экспериментальная и клиническая гастроэнтерология. 2010; 4: 3-13.
19. Grinevich V.B., Sas E. I. Physiological effects of bile acids. RMJ. Medical review. 2017;(2):87-91. (in Russ.)@@ В. Б. Гриневич, Е. И. Сас. Физиологические эффекты желчных кислот. РМЖ. Медицинское обозрение. 2017; 2: 87-91.
20. Yevsyutina Yu.V., Ivashkin V. T. Metabolism of bile acids, liver diseases and microbiome.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):4-10. (In Russ.) doi: 10.22416/1382-4376-2018-28-2-4-10@@ Евсютина Ю. В., Ивашкин В. Т. Метаболизм желчных кислот, заболевания печени и микробиом. Рос журн гастроэнтерол гепатол колопроктол 2018; 28(2):4-10 doi: 10.22416/1382-4376-2018-28-2-4-10
21. Hofmann A.F., Hagey L. R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(16):2461-2483. doi:10.1007/s00018-008-7568-6
22. Hoffman I. Duodenogastroesophageal Reflux. Vandenplas Y. (eds) 2017 Gastroesophageal Reflux in Children. Springer, Cham. doi:10.1007/978-3-319-60678-1_17
23. Kawabe A., Shimada Y., Soma T., et al. Production of prostaglandinE2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells. Life Sci. 2004;75(1):21-34. doi:10.1016/j.lfs.2003.11.022
24. Duggan S.P., Behan F. M., Kirca M., et al. An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett’s oesophagus, which regulates NF-kappaB activation and cytokine levels. Carcinogenesis. 2010;31(5):936-945. doi:10.1093/carcin/bgq036
25. Zhang R., Gong J., Wang H., Wang L. Bile salts inhibit growth and induce apoptosis of cultured human normal esophageal mucosal epithelial cells. World J Gastroenterol. 2005; 11(41): 6466-6471.
26. Liu T., Zhang X., So C. K., et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007;28(2):488-496. doi:10.1093/carcin/bgl176
27. Morrow D.J., Avissar N. E., Toia L., et al. Pathogenesis of Barrett’s esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery. 2009;146(4):714-722. doi:10.1016/j.surg.2009.06.050
28. McQuaid K.R., Laine L., Fennerty M. B., Souza R., Spechler S. J. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34(2):146-165. doi:10.1111/j.1365-2036.2011.04709.x
29. Dvorak K., Watts G. S., Ramsey L., et al. Expression of bile acid transporting proteins in Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2009;104(2):302-309. doi:10.1038/ajg.2008.85
30. Hashimoto N. Cholecystectomy and Duodenogastric Reflux-: Reflux of Duodenal Content Induces Esophageal Carcinogenesis. Clin Surg. 2018; 3:1867.
31. Sun D., Wang X., Gai Z., Song X., Jia X., Tian H. Bile acids but not acidic acids induce Barrett’s esophagus.Int J Clin Exp Pathol. 2015;8(2):1384-1392. Published 2015 Feb 1.
32. Hyvärinen H. Relationship of previous cholecystectomy to oesophagitis and gastroduodenal ulcers. Hepatogastroenterology. 1987;34(2):74-80. PMID: 3596461.
33. Jazrawi S., Walsh T. N., Byrne P. J., et al. Cholecystectomy and oesophageal reflux: a prospective evaluation. Br J Surg. 1993;80(1):50-3. doi: 10.1002/bjs.1800800119
34. McNamara D.A., O’Donohoe M.K., Horgan P. G., et al. Symptoms of oesophageal reflux are more common following laparoscopic cholecystectomy than in a control population. Ir J Med Sci. 1998;167(1):11-3. doi: 10.1007/BF02937544
35. Manifold D.K., Anggiansah A., Owen W. J. Effect of cholecystectomy on gastroesophageal and duodenogastric reflux. Am J Gastroenterol. 2000;95(10):2746-50. doi: 10.1111/j.1572-0241.2000.02298.x. PMID: 11051343.
36. Lin O.S., Kozarek R. A., Arai A., et al. The association between cholecystectomy and gastroesophageal reflux symptoms: a prospective controlled study. Ann Surg. 2010;251(1):40-5. doi: 10.1097/SLA.0b013e3181b9eca4
37. Zaninotto G., Portale G., Parenti A., Lanza C., Costantini M., Molena D., Ruol A., Battaglia G., Costantino M., Epifani M., Nicoletti L. Role of acid and bile reflux in development of specialised intestinal metaplasia in distal oesophagus. Dig Liver Dis. 2002 Apr;34(4):251-7. doi: 10.1016/s1590-8658(02)80144-x
38. Xiong L.S., Chen M. H., Lin J. K., Hu P. J. Stratification and symptom characteristics of non-erosive reflux disease based on acid and duodenogastroesophageal reflux. J Gastroenterol Hepatol. 2008 Feb;23(2):290-5. doi: 10.1111/j.1440-1746.2007.05152.x
39. Vaezi M.F., Richter J. E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111(5):1192-1199. doi:10.1053/gast.1996.v111.pm8898632
40. Nehra D., Howell P., Williams C. P., Pye J. K., Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44(5):598-602. doi:10.1136/gut.44.5.598
41. Monaco L., Brillantino A., Torelli F., Schettino M., Izzo G., Cosenza A., Di Martino N. Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors. World J Gastroenterol. 2009; 15(3):334-338.
42. Kunsch S., Neesse A., Huth J., et al. Increased Duodeno-Gastro-Esophageal Reflux (DGER) in symptomatic GERD patients with a history of cholecystectomy. Z Gastroenterol. 2009;47(8):744-748. doi:10.1055/s-0028-1109176
43. Freedman J., Ye W., Näslund E., Lagergren J. Association between cholecystectomy and adenocarcinoma of the esophagus. Gastroenterology. 2001;121(3):548-553. doi:10.1053/gast.2001.27217
44. Uspenskiy Y.P., Ivanov S. V., Vovk A. V. The evolution of approaches to the gallstone disease treatment. Diary of the Kazan Medical School. 2018; 4(22). 109-116. (in Russ.)@@ Успенский Ю. П., Иванов С. В., Вовк А. В. Эволюция подходов к лечению желчнокаменной болезни. Дневник Казанской медицинской школы 2018; 4(22):109-116.
45. Lagergren J., Mattsson F. Cholecystectomy as a risk factor for oesophageal adenocarcinoma. Br J Surg. 2011;98(8):1133-37. doi: 10.1002/bjs.7504. PMID: 21590760.
46. Tack J. Review article: role of pepsin and bile in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22 Suppl 1:48-54. doi:10.1111/j.1365-2036.2005.02609.x
47. Eldredge T.A., Myers J. C., Kiroff G. K., Shenfine J. Detecting Bile Reflux-the Enigma of Bariatric Surgery. Obes Surg. 2018;28(2):559-566. doi:10.1007/s11695-017-3026-6
48. Yusupova A.F., Valiullina N. M., Odintsova A. Kh. Dynamic scintigraphy of hepatobiliary system in the diagnosis of post-cholecystectomy syndrome. Kazan Medical Journal. 2007;88(1):44-46. (in Russ.)@@ А. Ф. Юсупова, Н. М. Валиуллина, А. Х. Одинцова. Динамическая сцинтиграфия гепатобилиарной системы в диагностике постхолецистэктомического синдрома. Казанский медицинский журнал, 2007;88(1):44-46.
49. Pace F., Sangaletti O., Pallotta S., Molteni P., Porro G. B. Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand J Gastroenterol. 2007;42(9):1031-1039. doi:10.1080/00365520701245645
50. Frazzoni M., de Bortoli N., Frazzoni L., Tolone S., Savarino V., Savarino E. Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. Dig Dis Sci. 2017 Aug;62(8):1881-1889. doi: 10.1007/s10620-017-4625-8
51. Tack J., Bisschops R., Koek G., Sifrim D., Lerut T., Janssens J. Dietary restrictions during ambulatory monitoring of duodenogastroesophageal reflux. Dig Dis Sci. 2003 Jul;48(7):1213-20. doi: 10.1023/a:1024130419914
52. Karamanolis G., Vanuytsel T., Sifrim D., Bisschops R., Arts J., Caenepeel P., Dewulf D., Tack J. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci. 2008 Sep;53(9):2387-93. doi: 10.1007/s10620-007-0186-6
53. Tack J., Koek G., Demedts I., Sifrim D., Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004 Jun;99(6):981-8. doi: 10.1111/j.1572-0241.2004.04171.x
54. Koek G.H., Vos R., Flamen P., Sifrim D., Lammert F., Vanbilloen B., Janssens J., Tack J. Oesophageal clearance of acid and bile: a combined radionuclide, pH, and Bilitec study. Gut. 2004 Jan;53(1):21-6. doi: 10.1136/gut.53.1.21
55. Sifrim D., Holloway R., Silny J., Xin Z., Tack J., Lerut A., Janssens J. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology. 2001 Jun;120(7):1588-98. doi: 10.1053/gast.2001.24841
56. Maselli R., Inoue H., Ikeda H., et al. Endoscopic Ex Vivo Evaluation of Bile Concentrations by Narrow Band Imaging: A Pilot Study. Gastroenterol Res Pract. 2015;2015:367848. doi: 10.1155/2015/367848
57. Kunsch S., et al. Impact of Pantoprazole on Duodeno-Gastro-Esophageal Reflux (DGER). Z Gastroenterol. 2009; 47: 277-282.
58. Turcotte S., Duranceau A., et al. Gastroesophageal reflux and cancer. Thorac Surg Clin. 2005;15:341-52.
59. Woodland P., Batista-Lima F., et al. Topical protection of human esophageal mucosal integrity. Am J Physiol Gastrointest Liver Physiol. 2015;308: G975-80.
60. Xin Y., Dai N., Zhao L., Wang J. G., Si J. M. The effect of famotidine on gastroesophageal and duodeno-gastro-esophageal refluxes in critically ill patients. World J Gastroenterol. 2003 Feb;9(2):356-8. doi: 10.3748/wjg.v9.i2.356
61. Menges M., Müller M., Zeitz M. Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol. 2001 Feb;96(2):331-7. doi: 10.1111/j.1572-0241.2001.03515.x
62. Netzer P., Gut A., Brundler R., Gaia C., Halter F., Inauen W. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther. 2001 Sep;15(9):1375-84. doi: 10.1046/j.1365-2036.2001.01069.x
63. Savarino V., Marabotto E., Zentilin P., Demarzo M. G., de Bortoli N., Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Des Devel Ther. 2021 Apr 19;15:1609-1621. doi: 10.2147/DDDT.S306371
64. Yachimski P., Maqbool S., Bhat Y. M., Richter J. E., Falk G. W., Vaezi M. F. Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett’s esophagus. Am J Gastroenterol. 2015 Aug;110(8):1143-8. doi: 10.1038/ajg.2015.161
65. Kunsch S., Neesse A., Linhart T., Nell C., Gress T. M., Ellenrieder V. Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion. 2012;86(4):315-22. doi: 10.1159/000342234
66. Paterson W.G., Wang H., Beck I. T. The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH-metry study. Am J Gastroenterol. 1997; 92:226-230.
67. Smythe A., Bird N., Troy G., Globe J., Johnson A. G. Effect of cisapride on oesophageal motility and duodeno-gastro-oesophageal reflux in patients with Barrett’s oesophagus. Eur J Gastroenterol Hepatol. 1997; 9:1-5.
68. Smythe A., Bird N. C., Troy G. P., Ackroyd R., Johnson A. G. Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro-oesophageal reflux in patients with Barrett’s oesophagus? Eur J Gastroenterol Hepatol. 2003 Mar;15(3):305-12. doi: 10.1097/00042737-200303000-00014
69. Koek G.H., Sifrim D., Lerut T., Janssens J., Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52(10):1397-1402. doi:10.1136/gut.52.10.1397
70. Akiyama J., Kuribayashi S., Baeg M. K., de Bortoli N., Valitova E., Savarino E. V., Kusano M., Triadafilopoulos G. Current and future perspectives in the management of gastroesophageal reflux disease. Ann N Y Acad Sci. 2018 Dec;1434(1):70-83. doi: 10.1111/nyas.13850
71. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 2:10-6. doi: 10.1111/j.1365-2036.2006.03040.x
72. Scarpellini E., Ang D., Pauwels A., De Santis A., Vanuytsel T., Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13(5):281-294. doi:10.1038/nrgastro.2016.50
73. Peng S., Huo X., Rezaei D., et al. In Barrett’s esophagus patients and Barrett’s cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307(2): G129-G139. doi:10.1152/ajpgi.00085.2014
74. Banerjee B., Shaheen N. J., Martinez J. A., et al. Clinical Study of Ursodeoxycholic Acid in Barrett’s Esophagus Patients. Cancer Prev Res (Phila). 2016;9(7):528-533. doi:10.1158/1940-6207.CAPR-15-0276
75. Martynov A.I., Sheptulin A. A., Mayev I. V., et al. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7-14. (In Russ.) doi:10.22416/1382-4376-2020-30-2-7-14@@ Мартынов А. И., Шептулин А. А., Маев И. В., Казюлин А. Н., Каратеев А. Е., Мелехов А. В., Пальгова Л. К., Райхельсон К. Л. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):7-14. doi:10.22416/1382-4376-2020-30-2-7-14
76. Uspensky Yu.P., Fominykh Yu.A., Gnutov A. A., Filippova V. N. Duodenogastroesophageal reflux and biliary tract pathology. Pharmateca. 2021; 28 (2): 54-59. (In Russ.) doi:10.18565/pharmateca.2021.2.54-59@@ Успенский Ю. П., Фоминых Ю. А., Гнутов А. А., Филиппова В. Н. Дуоденогастроэзофагеальный рефлюкс и патология билиарного тракта. Фарматека. 2021;28(2):54-59 doi:10.18565/pharmateca.2021.2.54-59
77. Zvyaglova M.Y., Knyazev O. V., Parfenov A. I. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Terapevticheskii arkhiv. 2020;92(2):104-111. (In Russ.) doi: 10.26442/00403660.2020.02.000569@@ Звяглова М. Ю., Князев О. В., Парфенов А. И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020;92(2):104-111. doi: 10.26442/00403660.2020.02.000569
78. Reimer C., et al. Concentrated Alginate As Add-On Therapy in Gastro-Esophageal Reflux Disease (GERD) Patients With Inadequate Response to Once Daily Proton Pump Inhibitor (PPI): A Multicentre, Randomized, Double-Blind, Placebo-Controlled Pilot Study. Gastroenterology. 2015; 148:135-136.
79. Uspensky Yu.P., Pakhomova I. G., Tkachenko E. I. The first experience of using “Gaviscon” in Russia in the treatment of gastroesophageal reflux disease.Russian Medical Journal. 2007; 15 (22): 1-4. (In Russ.)@@ Успенский Ю. П., Пахомова И. Г., Ткаченко Е. И. Первый в России опыт использования «Гевискона» в лечении гастроэзофагеальной рефлюксной болезни. Русский медицинский журнал. 2007; 15(22):1-4.
80. Rohof W., Bennink R., et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gasterenterol Hepatol. 2013;11:1585-91.
81. Strugala V., Avis J., Jolliffe I. G., Johnstone L. M., Dettmar P. W. The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? J Pharm Pharmacol. 2009 Aug;61(8):1021-8. doi: 10.1211/jpp/61.08.0005
82. Vaezi M.F., Fass R., Vakil N., et al. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology. 2020 Jun;158(8):2093-2103. doi: 10.1053/j.gastro.2020.02.031
Рецензия
Для цитирования:
Фоминых Ю.А., Гнутов А.А., Насыров Р.А., Калинина Е.Ю., Колгина Н.Ю. Особенности поражения пищевода при постхолецистэктомическом синдроме. Экспериментальная и клиническая гастроэнтерология. 2022;(2):121-130. https://doi.org/10.31146/1682-8658-ecg-198-2-121-130
For citation:
Fominykh Yu.A., Gnutov A.A., Nasyrov R.A., Kalinina E.Yu., Kolgina N.Yu. Features of esophageal lesion in postcholecystectomy syndrome. Experimental and Clinical Gastroenterology. 2022;(2):121-130. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-198-2-121-130